Genitech Vnsan Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 24-10-2024
- Paid Up Capital ₹ 0.10 M
as on 24-10-2024
- Company Age 6 Year, 18 Days
- Last Filing with ROC 31 Mar 2024
- Revenue 35.62%
(FY 2023)
- Profit -44.37%
(FY 2023)
- Ebitda -84.29%
(FY 2023)
- Net Worth -66.38%
(FY 2023)
- Total Assets 59.16%
(FY 2023)
About Genitech Vnsan Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Vijender Kumar and Deepak Kumar serve as directors at the Company.
- CIN/LLPIN
U52609DL2018PTC343129
- Company No.
343129
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Dec 2018
- Date of AGM
19 Jul 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Genitech Vnsan Pharmaceuticals Private Limited offer?
Genitech Vnsan Pharmaceuticals Private Limited offers a wide range of products and services, including Packaging, Laminated & Zip Bags, Biodegradable and Compostable Bags, Health Conditions, Bone, Joint & Muscle Care.
Who are the key members and board of directors at Genitech Vnsan Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vijender Kumar  | Director | 20-May-2023 | Current |
| Deepak Kumar | Director | 01-Jun-2023 | Current |
Financial Performance of Genitech Vnsan Pharmaceuticals.
Genitech Nsan Pharmaceutical Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 35.62% increase. The company also saw a substantial fall in profitability, with a 44.37% decrease in profit. The company's net worth observed a substantial decline by a decrease of 66.38%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Genitech Vnsan Pharmaceuticals?
In 2023, Genitech Vnsan Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Genitech Vnsan Pharmaceuticals?
Genitech Vnsan Pharmaceuticals has a workforce of 171 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Genitech Vnsan Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genitech Vnsan Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
